藏红花是传统藏医药中的草药。藏红花提取物已被证实能够抑制多种癌症，包括胶质瘤，且促进肿瘤细胞凋亡，但具体机制尚不清楚。本研究采用网络药理学和生物信息学分析方法，以研究藏红花对胶质瘤的作用机制。我们使用在线数据库获取藏红花的活性成分及其靶点。胶质瘤相关的靶点也从在线数据库中获取。我们将药物靶点与胶质瘤相关的靶点进行交集，并进行蛋白质相互作用网络分析以获取网络核心基因。随后，我们从The Cancer Genome Atlas (TCGA)数据库获取了胶质瘤患者的RNA-seq数据。通过不同表达分析和Lasso回归，进一步筛选了网络中的核心基因，并建立了预测模型。利用该模型，将样本分为高风险组和低风险组。我们使用中国胶质瘤基因组图谱 (CGGA)数据库的RNA-seq数据进一步验证了我们的预测模型。然后，我们探索了高风险患者和低风险患者在通路富集方面的差异，并计算了两组之间的免疫微环境差异。最后，我们使用CGGA数据库中的单细胞RNA-seq数据分析了模型基因主要富集的细胞类型，并预测了藏红花对哪些细胞类型产生影响。 © 2023. 作者(们), 授予 Springer Science+Business Media, LLC 独家许可，隶属于 Springer Nature。

Saffron crocus is a herbal medicine of traditional Tibetan medicine (TTM). Saffron extract has been indicated to inhibit tumor cell growth and promote tumor cell apoptosis in a variety of cancers, including glioma, but the specific mechanism is not clear. To study the possible mechanism of saffron action on glioma, network pharmacology and bioinformatics analysis methods were used in this study. We used the online database to obtain the active ingredients of saffron and their targets. Glioma-related targets were also acquired from online database. We intersected drug targets with glioma-related targets and conducted PPI network analysis to obtain network core genes. Then, we obtained RNA-seq data from The Cancer Genome Atlas (TCGA) database for glioma patients. Through different expression analysis and lasso regression, further screening of core genes in the network was conducted, and a prognostic model was established. The sample was divided into two groups with high and low risk using this model. The RNA-seq data from the Chinese Glioma Genome Atlas (CGGA) database were used to further validate our prediction model. Then, we explored the difference in pathways enrichment between high-risk patients and low-risk patients and calculated the difference in immune microenvironment between the two groups. Finally, we used scRNA-seq data in the CGGA database to analyze the cell types in which the model gene is mainly enriched and predicted the cell types which saffron effected on.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.